Lilly raises diabetes weight-loss bar with amylin-Zepbound combo

Science

Lilly Raises Diabetes Weight-Loss Bar With Amylin-Zepbound Combo

By Fierce Biotech

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling with both obesity or overweight and type 2 diabetes, topping its own triple-G drug candidate retatrutide in that traditionally t ...Read more

Related Posts

Japan's 2011 tsunami sparked fish hybridization, but species boundaries largely held

Japan's 2011 tsunami sparked fish hybridization, but species boundaries largely held

Sep 27, 2026
Her son was dying, but his rare cancer made it difficult to get the right drug

Her son was dying, but his rare cancer made it difficult to get the right drug

Sep 21, 2026
Living with real-time progress in lung cancer treatment : NPR

Living with real-time progress in lung cancer treatment : NPR

Sep 27, 2026
A microprotein atlas of the human frontal cortex in Alzheimer’s disease

A microprotein atlas of the human frontal cortex in Alzheimer’s disease

Sep 14, 2026
We use cookies to help provide you with the best experience when you visit our websites. By using this site you consent to the use of cookies on your device. see our cookie policy.